Xtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above Two Hundred Day Moving Average – Should You Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.55. Xtant Medical shares last traded at $0.52, with a volume of 27,928 shares.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 price target on Xtant Medical and gave the company a “buy” rating in a report on Friday, October 18th.

Xtant Medical Trading Up 0.6 %

The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $72.29 million, a PE ratio of -4.00 and a beta of 0.33.

Xtant Medical (NYSEAMERICAN:XTNT) last released its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The firm had revenue of $27.94 million during the quarter. Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%.

Institutional Trading of Xtant Medical

An institutional investor recently bought a new position in Xtant Medical stock. Evernest Financial Advisors LLC purchased a new stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 40,000 shares of the medical device company’s stock, valued at approximately $27,000. 69.33% of the stock is currently owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.